flecainide has been researched along with Tachycardia, Paroxysmal in 50 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Tachycardia, Paroxysmal: Abnormally rapid heartbeats with sudden onset and cessation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide." | 9.08 | Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. ( Buxton, AE; Heilman, JM; Hopson, JR; Kienzle, MG; Nademanee, K; Rinkenberger, RL, 1996) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 9.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2)." | 9.07 | Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. ( DaTorre, SD; Hougham, AJ; McCarville, SE; Platt, ML; Pritchett, EL, 1991) |
| "The effect of flecainide in 12 patients with the Wolff-Parkinson-White syndrome was analyzed with respect to the anterograde and retrograde conduction properties of the accessory pathway, the modes of initiation and termination of circus movement tachycardias, and the ventricular response during induced atrial fibrillation." | 7.66 | Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. ( Berthold, R; Buss, J; Krämer, A; Mitrović, V; Musial, WJ; Neuss, H; Schlepper, M, 1983) |
| "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide." | 5.08 | Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group. ( Buxton, AE; Heilman, JM; Hopson, JR; Kienzle, MG; Nademanee, K; Rinkenberger, RL, 1996) |
| "In order to compare the long-term safety of flecainide and propafenone, an open label, randomized, parallel group study was performed in 335 patients with paroxysmal atrial fibrillation (n = 200) or paroxysmal supraventricular tachycardia (n = 135), and no history of heart disease." | 5.08 | Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. ( Casadei, G; Chimienti, M; Cullen, MT, 1995) |
| "The dose-response relations for efficacy and tolerance of the antiarrhythmic drug flecainide acetate were studied in 28 patients with paroxysmal supraventricular tachycardia (Group 1) and 45 patients with paroxysmal atrial fibrillation or flutter (Group 2)." | 5.07 | Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. ( DaTorre, SD; Hougham, AJ; McCarville, SE; Platt, ML; Pritchett, EL, 1991) |
| " By means of telemedicine, it was possible to document the arrhythmia--in this case atrial fibrillation--within 10 days and to start antiarrhythmic drug treatment with flecainide and metoprolol." | 3.73 | Use of telemedicine in the diagnosis of paroxysmal atrial fibrillation and to monitor the effect of antiarrhythmic drug therapy. ( Israel, CW; Klingenheben, T, 2006) |
| "The effect of flecainide in 12 patients with the Wolff-Parkinson-White syndrome was analyzed with respect to the anterograde and retrograde conduction properties of the accessory pathway, the modes of initiation and termination of circus movement tachycardias, and the ventricular response during induced atrial fibrillation." | 3.66 | Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. ( Berthold, R; Buss, J; Krämer, A; Mitrović, V; Musial, WJ; Neuss, H; Schlepper, M, 1983) |
| "Flecainide has been shown to be effective in short-term, controlled studies for prevention of paroxysmal supraventricular tachycardia (SVT) and paroxysmal atrial fibrillation (AF)." | 2.67 | Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group. ( Anderson, JL; Fox, TL; Guarnieri, T; Maser, MJ; Platt, ML; Pritchett, EL, 1994) |
| " Only 3 (5%) of 66 patients discontinued therapy due to possible noncardiac adverse effects." | 2.67 | Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators. ( Anderson, JL, 1992) |
| "Oral flecainide acetate was administered to 34 patients with documented symptomatic paroxysmal supraventricular tachycardia (PSVT) with a double-blind, placebo-controlled, 8-week crossover trial design." | 2.67 | Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. ( Alpert, BL; Anderson, JL; Bhandari, AK; Gilbert, EM; Hawkinson, RW; Henthorn, RW; Pritchett, EL; Waldo, AL, 1991) |
| "Flecainide was replaced with encainide (153 mg/day; range, 50-225 mg/day) for a mean duration of 6." | 2.67 | Encainide versus flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias. ( Coumel, P, 1990) |
| "Flecainide for the treatment of supraventricular tachycardia (SVT) in newborns is still controversial because of its potentially severe proarrhythmic effects." | 1.35 | Flecainide as first-line treatment for supraventricular tachycardia in newborns. ( Bonanomi, C; Centola, M; Colli, AM; Danzi, GB; Ferlini, M; Galli, MA; Ravaglia, R; Salice, P; Salvini, L, 2009) |
| "Patient 1 had frequent episodes of paroxysmal atrial fibrillation resistant to Class IA drugs." | 1.30 | ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. ( Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M, 1999) |
| "Propafenone was administered to 32 patients, with positive results in 15 (46." | 1.28 | Long-term follow-up of patients with inducible supraventricular tachycardia treated with flecainide or propafenone: therapy guided by transesophageal electropharmacologic testing. ( Bertoldi, A; Dallago, M; Del Greco, M; Furlanello, F; Guarnerio, M; Inama, G; Vergara, G, 1992) |
| "Propafenone was tested in 13 patients (43." | 1.28 | [Electropharmacological test with class-I C drugs in paroxysmal supraventricular re-entrant tachycardia: is a negative result with a drug predictive of the ineffectiveness of other drugs of the same class?]. ( Braito, G; Furlanello, F; Guarnerio, M; Inama, G; Vergara, G, 1991) |
| "When amiodarone was not employed, as a first choice, in conformity with a specific protocol, it was utilized as a second choice after verapamil or flecainide." | 1.28 | [Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches]. ( Bechi, S; Cordoni, M; Franchini, C; Mazza, F; Micheli, G; Scalzini, A, 1989) |
| "Flecainide acetate is an effective agent for the acute termination of both orthodromic AV and intra-AV nodal reentrant tachycardias." | 1.27 | Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias. ( Bexton, RS; Camm, AJ; Hellestrand, KJ; Nathan, AW; Spurrell, RA, 1983) |
| "Flecainide acetate is a recently introduced, class 1 antiarrhythmic agent that is highly effective in the treatment of ventricular and atrioventricular/nodal reentrant tachycardias." | 1.27 | Pacing failure due to flecainide acetate. ( Clarke, LM; James, MA; Papouchado, M; Walker, PR, 1985) |
| "Flecainide acetate is an effective antiarrhythmic agent for the acute termination of recent onset paroxysmal atrial and ventricular tachyarrhythmias." | 1.27 | Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias. ( Bexton, RS; Camm, AJ; Hellestrand, KJ; Nathan, AW, 1987) |
| "Thus flecainide is an highly effective and well tolerated drug for the control of PSVT in infancy." | 1.27 | [Electrophysiological effects and clinical efficacy of flecainide in childhood patients with supraventricular reciprocating paroxysmal tachycardia]. ( Cavallaro, C; D'Onofrio, A; Della Gatta, O; Marsico, F; Musto, A; Musto, B, 1987) |
| " It allows a reduction in the dosage of amiodarone when both drugs are combined." | 1.27 | Long term evaluation of flecainide acetate in supraventricular tachyarrhythmias. ( Mary-Rabine, L; Telerman, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (32.00) | 18.7374 |
| 1990's | 25 (50.00) | 18.2507 |
| 2000's | 6 (12.00) | 29.6817 |
| 2010's | 2 (4.00) | 24.3611 |
| 2020's | 1 (2.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsai, CF | 1 |
| Chuang, YT | 1 |
| Chang, KW | 1 |
| Sivalingam, SK | 1 |
| Gadiraju, VT | 1 |
| Hariharan, MV | 1 |
| Atreya, AR | 1 |
| Flack, JE | 1 |
| Aziz, H | 1 |
| Tsai, TF | 1 |
| Garcia, RT | 1 |
| Bui, JQ | 1 |
| Thinda, A | 1 |
| Amsterdam, EA | 1 |
| Drewitz, I | 1 |
| Rostock, T | 1 |
| Hoffmann, B | 1 |
| Steven, D | 1 |
| Servatius, H | 1 |
| Meinertz, T | 1 |
| Willems, S | 1 |
| Ferlini, M | 1 |
| Colli, AM | 1 |
| Bonanomi, C | 1 |
| Salvini, L | 1 |
| Galli, MA | 1 |
| Salice, P | 1 |
| Ravaglia, R | 1 |
| Centola, M | 1 |
| Danzi, GB | 1 |
| Morady, F | 1 |
| Klingenheben, T | 1 |
| Israel, CW | 1 |
| Liakishev, AA | 1 |
| Neuss, H | 2 |
| Buss, J | 1 |
| Schlepper, M | 1 |
| Berthold, R | 1 |
| Mitrović, V | 1 |
| Krämer, A | 1 |
| Musial, WJ | 1 |
| Hellestrand, KJ | 4 |
| Nathan, AW | 4 |
| Bexton, RS | 4 |
| Spurrell, RA | 2 |
| Camm, AJ | 5 |
| Hamer, AW | 1 |
| Strathmore, N | 1 |
| Vohra, JK | 1 |
| Hunt, VD | 1 |
| Wang, JA | 1 |
| Lau, CP | 1 |
| Tai, YT | 1 |
| Wu, BZ | 1 |
| Knez, A | 1 |
| Haberl, R | 1 |
| Steinbeck, G | 1 |
| Anderson, JL | 4 |
| Platt, ML | 2 |
| Guarnieri, T | 1 |
| Fox, TL | 1 |
| Maser, MJ | 2 |
| Pritchett, EL | 4 |
| Santinelli, V | 1 |
| Arnese, M | 1 |
| Oppo, I | 1 |
| Matarazzi, C | 1 |
| Maione, S | 1 |
| Palma, M | 1 |
| Giunta, A | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Manz, M | 1 |
| Lüderitz, B | 1 |
| Mannino, MM | 1 |
| Mehta, D | 1 |
| Gomes, JA | 1 |
| Hopson, JR | 1 |
| Buxton, AE | 1 |
| Rinkenberger, RL | 1 |
| Nademanee, K | 1 |
| Heilman, JM | 1 |
| Kienzle, MG | 1 |
| Dorian, P | 1 |
| Naccarelli, GV | 1 |
| Coumel, P | 2 |
| Hohnloser, SH | 1 |
| Chimienti, M | 1 |
| Cullen, MT | 2 |
| Casadei, G | 1 |
| Matteucci, C | 1 |
| Busi, G | 1 |
| Fujiki, A | 1 |
| Usui, M | 1 |
| Nagasawa, H | 1 |
| Mizumaki, K | 1 |
| Hayashi, H | 1 |
| Inoue, H | 1 |
| Alboni, P | 1 |
| Tomasi, C | 1 |
| Menozzi, C | 1 |
| Bottoni, N | 1 |
| Paparella, N | 1 |
| Fucà, G | 1 |
| Brignole, M | 1 |
| Cappato, R | 1 |
| Furlanello, F | 2 |
| Guarnerio, M | 2 |
| Inama, G | 2 |
| Vergara, G | 2 |
| Del Greco, M | 1 |
| Bertoldi, A | 1 |
| Dallago, M | 1 |
| Musto, B | 3 |
| Cavallaro, C | 3 |
| Musto, A | 3 |
| D'Onofrio, A | 3 |
| Belli, A | 1 |
| De Vincentis, L | 1 |
| Bhandari, AK | 2 |
| Gilbert, EM | 2 |
| Alpert, BL | 2 |
| Henthorn, RW | 2 |
| Waldo, AL | 2 |
| Hawkinson, RW | 2 |
| Benditt, DG | 1 |
| Dunnigan, A | 1 |
| Buetikofer, J | 1 |
| Milstein, S | 1 |
| DaTorre, SD | 1 |
| McCarville, SE | 1 |
| Hougham, AJ | 1 |
| Braito, G | 1 |
| Bashir, Y | 1 |
| Finzi, A | 1 |
| Potenza, S | 1 |
| Guenzati, G | 1 |
| Walker, PR | 1 |
| Papouchado, M | 1 |
| James, MA | 1 |
| Clarke, LM | 1 |
| Cordoni, M | 1 |
| Scalzini, A | 1 |
| Bechi, S | 1 |
| Franchini, C | 1 |
| Mazza, F | 1 |
| Micheli, G | 1 |
| Della Gatta, O | 1 |
| Marsico, F | 1 |
| Mary-Rabine, L | 1 |
| Telerman, M | 1 |
| Marwick, TH | 1 |
| Woodhouse, SP | 1 |
| Greco, R | 1 |
| Hoff, PI | 1 |
| Tronstad, A | 1 |
| Oie, B | 1 |
| Ohm, OJ | 1 |
| Casciani, M | 1 |
| Podestà, M | 1 |
| Carolis, S | 1 |
| Bargellini, F | 1 |
| Anticoli Borza, S | 1 |
| Kim, SS | 1 |
| Lal, R | 1 |
| Ruffy, R | 1 |
| Slama, R | 1 |
| LeClercq, JF | 1 |
3 reviews available for flecainide and Tachycardia, Paroxysmal
| Article | Year |
|---|---|
[Current strategies in the treatment of atrial fibrillation].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiac Pacing, Artificial; Catheter Ab | 2008 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
16 trials available for flecainide and Tachycardia, Paroxysmal
| Article | Year |
|---|---|
[Circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. Results of the APAF trial].
Topics: Adolescent; Adult; Aged; Amiodarone; Angina, Unstable; Anti-Arrhythmia Agents; Atrial Fibrillation; | 2008 |
Oral flecainide, sotalol, and verapamil for the termination of paroxysmal supraventricular tachycardia.
Topics: Administration, Oral; Adult; Cardiac Pacing, Artificial; Female; Flecainide; Humans; Male; Middle Ag | 1993 |
Effects of flecainide on exercise hemodynamics and electrocardiography in patients without structural heart disease.
Topics: Atrial Fibrillation; Blood Pressure; Cross-Over Studies; Double-Blind Method; Electrocardiography; E | 1995 |
[The use of digitalis glycosides in atrial fibrillation].
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Digoxin; Dose-Response Relationship, Drug; D | 1994 |
Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Adult; Aged; Confounding Factors, Epidemiologic; Female; Flecainide; Humans; Male; Middle Aged; Tach | 1994 |
Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function.
Topics: Adolescent; Adult; Blood Pressure; Echocardiography; Female; Flecainide; Heart Rate; Humans; Male; M | 1993 |
Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmia | 1996 |
A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Flecainide; | 1996 |
Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dose-Res | 1995 |
Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Diltiazem; D | 2001 |
Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators.
Topics: Atrial Fibrillation; Drug Evaluation; Drug Tolerance; Female; Flecainide; Follow-Up Studies; Humans; | 1992 |
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Administration, Oral; Double-Blind Method; Drug Administration Schedule; Female; Flecainide; Humans; | 1991 |
Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias.
Topics: Flecainide; Humans; Research Design; Tachycardia, Paroxysmal; Tachycardia, Supraventricular; Time Fa | 1991 |
Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Double-Blind Method; F | 1991 |
Clinical trials of flecainide acetate in the management of supraventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Flecainide; Humans; | 1990 |
Encainide versus flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias.
Topics: Adult; Anilides; Anti-Arrhythmia Agents; Atrial Fibrillation; Encainide; Female; Flecainide; Humans; | 1990 |
31 other studies available for flecainide and Tachycardia, Paroxysmal
| Article | Year |
|---|---|
A Peculiar Wide Complex Tachycardia During Flecainide Treatment.
Topics: Flecainide; Humans; Tachycardia; Tachycardia, Paroxysmal | 2022 |
Flecainide toxicity--treatment with intravenous fat emulsion and extra corporeal life support.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Extracorporeal Circulation; Fat Em | 2013 |
Confused and Too Long: Neurotoxicity and Cardiac Toxicity of Flecainide.
Topics: Aged; Anti-Arrhythmia Agents; Ataxia; Atrial Fibrillation; Atrioventricular Block; Cardiotoxicity; E | 2017 |
Flecainide as first-line treatment for supraventricular tachycardia in newborns.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography, Ambula | 2009 |
Wide QRS complexes during atrial fibrillation: what is the mechanism?
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrophysiology; Flecainide; Humans; Male; Middle Age | 2004 |
Use of telemedicine in the diagnosis of paroxysmal atrial fibrillation and to monitor the effect of antiarrhythmic drug therapy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography, Ambulatory; Female; Flecainide; Hu | 2006 |
Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome.
Topics: Adult; Electrophysiology; Female; Flecainide; Heart Conduction System; Humans; Male; Middle Aged; Pi | 1983 |
Cardiac electrophysiologic effects of flecainide acetate for paroxysmal reentrant junctional tachycardias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Female; Flecai | 1983 |
A comparison of the antiarrhythmic effects on AV junctional re-entrant tachycardia of oral and intravenous flecainide acetate.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrioventricular Node; Bundle | 1983 |
Current treatment options for paroxysmal supraventricular tachycardia.
Topics: Acute Disease; Catheter Ablation; Chronic Disease; Flecainide; Humans; Propafenone; Tachycardia, Atr | 1994 |
[Role of a "bystander" concealed accessory pathway in the response to verapamil and flecainide treatment in a patient with nodal reentry tachycardia].
Topics: Anti-Arrhythmia Agents; Child; Echocardiography; Electrocardiography, Ambulatory; Flecainide; Heart | 1996 |
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Hea | 1999 |
Long-term follow-up of patients with inducible supraventricular tachycardia treated with flecainide or propafenone: therapy guided by transesophageal electropharmacologic testing.
Topics: Adult; Cardiac Pacing, Artificial; Female; Flecainide; Follow-Up Studies; Humans; Male; Propafenone; | 1992 |
Flecainide single oral dose for management of paroxysmal supraventricular tachycardia in children and young adults.
Topics: Administration, Oral; Adolescent; Cardiac Pacing, Artificial; Child; Female; Flecainide; Follow-Up S | 1992 |
Flecainide for supraventricular tachyarrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Flecainide; Humans; Tachycardia, Paroxysmal; Tachycardia, | 1992 |
Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Atrial Fibrillation; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged; Predictive | 1992 |
[Electropharmacological test with class-I C drugs in paroxysmal supraventricular re-entrant tachycardia: is a negative result with a drug predictive of the ineffectiveness of other drugs of the same class?].
Topics: Adolescent; Adult; Cardiac Pacing, Artificial; Drug Evaluation; Electrocardiography; Female; Flecain | 1991 |
[His bundle block 2:1 during paroxysmal supraventricular tachycardia involving an occult accessory atrio-His pathway].
Topics: Bundle of His; Electrocardiography; Female; Flecainide; Heart Block; Heart Conduction System; Humans | 1990 |
Pacing failure due to flecainide acetate.
Topics: Aged; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Flecainide; Humans; Male; Piperidines; Tachy | 1985 |
[Supraventricular tachyarrhythmia of recent onset in the absence of documented cardiac pathology: different therapeutic approaches].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Electric Countershock; | 1989 |
Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; Flecainid | 1987 |
[Electrophysiological effects and clinical efficacy of flecainide in childhood patients with supraventricular reciprocating paroxysmal tachycardia].
Topics: Adolescent; Child; Child, Preschool; Electrocardiography; Female; Flecainide; Heart Conduction Syste | 1987 |
Long term evaluation of flecainide acetate in supraventricular tachyarrhythmias.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Electrocardiography; Fema | 1988 |
Use of flecainide acetate in the treatment of supraventricular tachyarrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Flecainide; Humans; Tachycardia, Paroxysm | 1988 |
Electrophysiologic effects and clinical efficacy of flecainide in children with recurrent paroxysmal supraventricular tachycardia.
Topics: Child; Electrophysiology; Female; Flecainide; Heart Conduction System; Humans; Male; Tachycardia, Pa | 1988 |
Electrophysiologic and clinical effects of flecainide for recurrent paroxysmal supraventricular tachycardia.
Topics: Adolescent; Adult; Aged; Cardiac Pacing, Artificial; Electrophysiology; Female; Flecainide; Humans; | 1988 |
[Wolff-Parkinson-White syndrome and anesthesia].
Topics: Adult; Amiodarone; Anesthesia, General; Female; Flecainide; Humans; Propranolol; Tachycardia, Paroxy | 1987 |
Treatment of paroxysmal reentrant supraventricular tachycardia with flecainide acetate.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Female; Fleca | 1986 |
Long term use of flecainide in patients with supraventricular tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Pipe | 1985 |
The clinical use of oral flecainide.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Piperidines; | 1985 |
Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Flecainide; Guinea Pigs; | 1985 |